ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerRowan Miller, Lucy Yates, David K. Chang et al.|Annals of Oncology|2020Cited by 478
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT DysregulationMarie‐Claude Gingras, Richard A. Gibbs, Kyle R. Covington et al.|Cell Reports|2016Cited by 149
High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterationsYiqun Zhang, Morten Muhlig Nielsen, Fengju Chen et al.|Nature Communications|2020Cited by 76